Search

Your search keyword '"Spire B"' showing total 763 results
Start Over Author "Spire B"
763 results on '"Spire B"'

1. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

Author

Salmon, D., Wittkop, L., Sogni, P., Esterle, L., Trimoulet, P., Izopet, J., Serfaty, L., Paradis, V., Spire, B., Carrieri, P., Valantin, M.A., Pialoux, G., Chas, J., Poizot-Martin, I., Barange, K., Naqvi, A., Rosenthal, E., Bicart-See, A., Bouchaud, O., Gervais, A., Lascoux-Combe, C., Goujard, C., Lacombe, K., Duvivier, C., Neau, D., Morlat, P., Bani-Sadr, F., Meyer, L., Boufassa, F., Autran, B., Roque, A.M., Solas, C., Fontaine, H., Costagliola, D., Piroth, L., Simon, A., Zucman, D., Boué, F., Miailhes, P., Billaud, E., Aumaitre, H., Rey, D., Peytavin, G., Petrov-Sanchez, V., Lebrasseur-Longuet, D., Chalouni, Mathieu, Pol, Stanislas, Sogni, Philippe, Fontaine, Hélène, Lacombe, Karine, Marc-Lacombe, Jean, Esterle, Laure, Dorival, Celine, Bourlière, Marc, Bani-Sadr, Firouzé, de Ledinghen, Victor, Zucman, David, Larrey, Dominique, Salmon, Dominique, Carrat, Fabrice, and Wittkop, Linda

Published
2021
Full Text
View/download PDF

2. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Author

Calmy, A, Tovar Sanchez, T, Kouanfack, C, Mpoudi-Etame, M, Leroy, S, Perrineau, S, Lantche-Wandji, M, Tetsa-Tata, D, Omgba-Bassega, P, Abong-Bwenda, T, Varloteaux, M, Tongo, M, Mpoudi-Ngolé, E, Montoyo, A, Mercier, N, LeMoing, V, Peeters, M, Reynes, J, Delaporte, E, Ayouba, A, Agholeng, A, Butel, C, Cournil, A, Eymard-Duvernay, S, Granouillac, B, Izard, S, Lacroix, A, Serrano, L, Vidal, N, Fouda, PJ, Mougnoutou, R, Olinga, J, Omgba, V, Tchokonte-Ngandé, SC, Ymele, B, Epoupa-Mpacko, CD, Fotso, M, Moukoko, R, Nké, T, Akamba, A, Lekelem, S, Tongo-Fotack, SB, Ngono, S, Tanga, M, Ebong, E, Edoul-Mbesse, G, Ciaffi, L, Koulla-Shiro, S, Manirakiza, G, Mimbé, ED, Boyer, S, Bousmah, M, Maradan, G, Nishimwe, ML, Spire, B, Lê, MP, Peytavin, G, Diallo, A, Fournier, I, Rekacewicz, C, Perez Casas, C, Calmy, Alexandra, Tovar Sanchez, Tamara, Kouanfack, Charles, Mpoudi-Etame, Mireille, Leroy, Sandrine, Perrineau, Ségolène, Lantche Wandji, Martial, Tetsa Tata, Darius, Omgba Bassega, Pierette, Abong Bwenda, Thérèse, Varloteaux, Marie, Tongo, Marcel, Mpoudi-Ngolé, Eitel, Montoyo, Alice, Mercier, Noémie, LeMoing, Vincent, Peeters, Martine, Reynes, Jacques, and Delaporte, Eric

Published
2020
Full Text
View/download PDF

5. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

Author

Meyer, L, Capitant, C, Charreau, I, Netzer, E, Leturque, N, Binesse, J, Foubert, V, Saouzanet, M, Euphrasie, F, Carette, D, Guillon, B, Saïdi, Y, Aboulker, J P, Spire, B, Suzan, M, Cattin, G, Demoulin, B, Sagaon-Teyssier, L, Lorente, N, Doré, V, Choucair, E, Le Mestre, S, Mennecier, A, Etien, N, Simon, M C, Diallo, A, Gibowski, S, Delfraissy, J F, Thompson, D, Sas, J, Pankovitch, J, Klein, M, Anis, A, Molina, Jean-Michel, Wainberg, Mark A, Trottier, Benoit, Tremblay, Cécile, Baril, Jean-Guy, Pialoux, Gilles, Cotte, Laurent, Chéret, Antoine, Pasquet, Armelle, Cua, Eric, Besnier, Michel, Rozenbaum, Willy, Chidiac, Christian, Delaugerre, Constance, Bajos, Nathalie, Timsit, Julie, Peytavin, Gilles, Fonsart, Julien, Durand-Zaleski, Isabelle, Meyer, Laurence, Aboulker, Jean-Pierre, Spire, Bruno, Suzan-Monti, Marie, Girard, Gabriel, Castro, Daniela Rojas, Préau, Marie, Morin, Michel, Thompson, David, Capitant, Catherine, Mennecier, Anaïs, Choucair, Elias, Doré, Véronique, Simon, Marie-Christine, Charreau, Isabelle, Otis, Joanne, Lert, France, Diallo, Alpha, Gibowski, Séverine, Rabian, Cecile, Chas, Julie, Tremblay, Cecile, Rojas-Castro, Daniela, Bernaud, Camille, Pintado, Claire, Sagaon-Teyssier, Luis, Mestre, Soizic Le, Ponscarme, Diane, and Doré, Veronique

Published
2017
Full Text
View/download PDF

7. CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada

Author

Ruiz-Burga, E. Tariq, S. Touloumi, G. Gill, J. Nicholls, E.J. Sabin, C. Mussini, C. Meyer, L. Volny Anne, A. Carlander, C. Grabar, S. Jarrin, I. Van Der Valk, M. Wittkop, L. Spire, B. Pantazis, N. Burns, F.M. Porter, K. and Ruiz-Burga, E. Tariq, S. Touloumi, G. Gill, J. Nicholls, E.J. Sabin, C. Mussini, C. Meyer, L. Volny Anne, A. Carlander, C. Grabar, S. Jarrin, I. Van Der Valk, M. Wittkop, L. Spire, B. Pantazis, N. Burns, F.M. Porter, K.

Abstract

Introduction Despite the availability of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART), 21 793 people were newly diagnosed with HIV in Europe in 2019. The Concerted action on seroconversion to AIDS and death in Europe study aims to understand current drivers of the HIV epidemic; factors associated with access to, and uptake of prevention methods and ART initiation; and the experiences, needs and outcomes of people with recently acquired HIV. Methods and analysis This longitudinal observational study is recruiting participants aged ≥16 years with documented laboratory evidence of HIV seroconversion from clinics in Canada and six European countries. We will analyse data from medical records, self-administered questionnaires, semistructured interviews and participatory photography. We will assess temporal trends in transmitted drug resistance and viral subtype and examine outcomes following early ART initiation. We will investigate patient-reported outcomes, well-being, and experiences of, knowledge of, and attitudes to HIV preventions, including PrEP. We will analyse qualitative data thematically and triangulate quantitative and qualitative findings. As patient public involvement is central to this work, we have convened a community advisory board (CAB) comprising people living with HIV. Ethics and dissemination All respective research ethics committees have approval for data to contribute to international collaborations. Written informed consent is required to take part. A dissemination strategy will be developed in collaboration with CAB and the scientific committee. It will include peer-reviewed publications, conference presentations and accessible summaries of findings on the study's website, social media and via community organisations. © The Author(s)

Published
2023

11. Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH).

Author

Barré, Tangui, Zucman, David, Marcellin, Fabienne, Ramier, Clémence, Protopopescu, Camelia, Tardieu, Raphaëlle, Ory, Karine, Salmon‐Céron, Dominique, Carrieri, Patrizia, Salmon, D., Wittkop, L., Sogni, P., Carrieri, P., Spire, B., Ory, K., Trimoulet, P., Izopet, J., Serfaty, L., Alric, L., and Valantin, M.A.

Subjects
HEPATITIS C virus, SUBSTANCE abuse, HIV, DRUG abuse
Abstract

By contrast, cannabis use was associated with a lower CD4/CD8 ratio (Table 1). 1 TABLE Factors associated with CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH cohort, mixed-effects linear regression model, 115 participants, 308 visits). Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH) Tobacco, alcohol, cannabis, and illicit drug use and their association with CD4/CD8 cell count ratio in people with controlled HIV: a cross-sectional study (ANRS CO3 AQUIVIH-NA-QuAliV). [Extracted from the article]

Published
2023
Full Text
View/download PDF

12. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]

Author

Michel, L, Lions, C, Winnock, M, Lang, J-P, Loko, M-A, Rosenthal, E, Marchou, B, Valantin, M-A, Morlat, P, Roux, P, Sogni, P, Spire, B, Poizot-Martin, I, Lacombe, K, Lascoux-Combe, C, Duvivier, C, Neau, D, Dabis, F, Salmon-Ceron, D, and Carrieri, M P

Published
2016
Full Text
View/download PDF

13. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

Author

Nordmann, S., Vilotitch, A., Roux, P., Esterle, L., Spire, B., Marcellin, F., Salmon‐Ceron, D., Dabis, F., Chas, J., Rey, D., Wittkop, L., Sogni, P., Carrieri, P., Salmon, D, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Valantin, M.A., Pialoux, G, Poizot‐Martin, I, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐See, A, Bouchaud, O, Gervais, A, Lascoux‐Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Bani‐Sadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, A.M., Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Couffin‐Cadiergues, S, Marchand, L, Salmon, D, Alagna, L, Sogni, P, Terris, B, Krivine, A, Katlama, C, Valantin, M.A., Stitou, H, Benhamou, Y, Charlotte, F, Fourati, S, Simon, A, Cacoub, P, Nafissa, S, Poizot‐Martin, I, Zaegel, O, Porcher, M, Tamalet, C, Pialoux, G, Chas, J, Slama, L, Callard, P, Bendjaballah, F, Le Pendeven, C, Marchou, B, Alric, L, Barange, K, Metivier, S, Selves, J, Larroquette, F, Rosenthal, E, Haudebourg, J, Saint‐Paul, M.C., Partouche, C, Bouchaud, O, Ziol, M, Baazia, Y, Uzan, M, Bicart‐See, A, Garipuy, D, Ferro‐Collados, M.J, Selves, J, Nicot, F, Gervais, A, Yazdanpanah, Y, Adle‐Biassette, H, Alexandre, G, Lascoux‐Combe, C, Molina, J.M, Bertheau, P, Duclos, J, Palmer, P, Lacombe, K, Campa, P, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Goujard, C, Pallier, C, Vittecoq, D, Lortholary, O, Duvivier, C, Shoai‐Tehrani, M, Mélard, A, Neau, D, Ochoa, A, Blanchard, E, Castet‐Lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐Buzy, L, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Morlat, P, Lacoste, D, Bonnet, F, Bernard, N, Bonarek Hessamfar, M, Roger‐Schmeltz, J, Gellie, P, Thibaut, P, Paccalin, F, Martell, C, Carmen Pertusa, M, Vandenhende, M, Mercier, P, Malvy, D, Pistone, T, Receveur, M.C, Caldato, S, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Zucman, D, Majerholc, C, Guitard, F, Boué, F, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Billaud, E, Raffi, F, Alavena, C, Rodallec, A, Miailhes, P, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Le‐Thi, T.T, Piroth, L, Chavanet, P, Duong Van Huyen, M, Buisson, M, Waldner‐Combernoux, A, Mahy, S, Binois, R, Simonet‐Lann, A.L, Croisier‐Bertin, D, Aumaître, H, Bani‐Sadr, F, Lambert, D, Nguen, Y, Rouger, C, Berger, J.L, Partrisiani, M, Gautner, P, Batard, M.L, Beniken, D, Lupin, C, Lions, C, Ritleng, A.‐S, Honoré, P, Payssan, V, Breau, S, Joulie, A, Mole, M, Bolliot, C, Touam, F, André, F, Hue, H, Larmet, L, Brochier, C, Thoirain, V, Raho‐Moussa, M, Ogoudjobi, S, Azar, M, Bornarel, D, Gohier, S, Chesnel, C, Maradan, G, Kurkdji, P, Hadjoudj, S, Malet, M, Kmiec, I, Fischer, P, Palacin, A, Pietri, M.P, Le Baut, V, Guet, P, Le Puil, S, Mebarki, M, Fior, A, Adda‐Lievin, A, Conte, V, Delaune, J, Dequae Merchadou, L, Douiri, N, Gillet, S, Gilbert, C, Jacquet, A, Kherraz, R, Lagorse, P, Mora, M, Protopopescu, C, and Rosellini, S

Published
2018
Full Text
View/download PDF

14. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

Author

Monge, S, Mocroft, A, Sabin, A, Touloumi, G, Sighem, A, Abgrall, S, Dray‐Spira, R, Spire, B, Castagna, A, Mussini, C, Zangerle, R, Hessamfar, M, Anderson, J, Hamouda, O, Ehren, K, Obel, N, Kirk, O, Antinori, A, Girardi, E, Saracino, A, Calmy, A, Wit, S, Wittkop, L, Bucher, C, Montoliu, A, Raben, D, Prins, M, Meyer, L, Chene, G, Burns, F, Amo, J, Judd, Ali, Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle, Ghosn, Jade, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Fätkenheuer, Gerd, Amo, Julia, Obel, Niels, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pérez‐Hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera‐Julian, Antoni, Antinori, Andrea, Monforte, Antonella, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo, Soriano‐Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miró, JoseM, Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Torti, Carlo, Sabin, Caroline, Teira, Ramon, Garrido, Myriam, Haerry, David, Wit, Stéphane, Miró, Mª, Costagliola, Dominique, dʼArminio‐Monforte, Antonella, Castagna, Antonella, Amo, Julia, Mocroft, Amanda, Raben, Dorthe, Chêne, Geneviève, Judd, Ali, Conejo, Pablo, Barger, Diana, Schwimmer, Christine, Termote, Monique, Wittkop, Linda, Campbell, Maria, Frederiksen, Casper M, Friis‐Møller, Nina, Kjaer, Jesper, Raben, Dorthe, Brandt, Rikke, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Bucher, Heiner, Cozzi‐Lepri, Alessandro, Dabis, François, Monforte, Antonella, Davies, Mary‐Anne, Amo, Julia, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Grabar, Sophie, Judd, Ali, Kirk, Ole, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Meyer, Laurence, Miró, Jose, Mocroft, Amanda, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Rohner, Eliane, Schomaker, Michael, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Thorne, Claire, Torti, Carlo, Valk, Marc, and Wittkop, Linda

Published
2018
Full Text
View/download PDF

15. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate ? emtricitabine for HIV pre?exposure prophylaxis

Author

Liegeon, Geoffroy, Antoni, Guillemette, Pialoux, Gilles, Capitant, Catherine, Cotte, Laurent, Charreau, Isabelle, Tremblay, Cécile, Cua, Eric, Senneville, Eric, Raffi, François, Meyer, Laurence, Molina, Jean?Michel, Meyer, L, Capitant, C, Charreau, I, Netzer, E, Leturque, N, Binesse, J, Foubert, V, Saouzanet, M, Euphrasie, F, Carette, D, Guillon, B, Saïdi, Y, Aboulker, J P., Spire, B, Suzan, M, Cattin, G, Demoulin, B, Sagaon?Teyssier, L, Lorente, N, Doré, V, Choucair, E, Le Mestre, S, Mennecier, A, Etien, N, Simon, M C., Diallo, A, Gibowski, S, Delfraissy, J F., Thompson, D, Sas, J, Pankovitch, J, Klein, M, Anis, A, Wainberg, Mark A., Trottier, Benoit, Baril, Jean?Guy, Chéret, Antoine, Pasquet, Armelle, Hall, Nolwenn, Rozenbaum, Willy, Chidiac, Christian, Delaugerre, Constance, Bajos, Nathalie, Timsit, Julie, Peytavin, Gilles, Fonsart, Julien, Durand?Zaleski, Isabelle, Aboulker, Jean?Pierre, Spire, Bruno, Suzan?Monti, Marie, Girard, Gabriel, Castro, Daniela Rojas, Préau, Marie, Morin, Michel, Thompson, David, Mennecier, Anaïs, Choucair, Elias, Doré, Véronique, Simon, Marie?Christine, Otis, Joanne, Lert, France, Diallo, Alpha, Gibowski, Séverine, and Rabian, Cecile

Subjects
Testing, Prevention, Patient outcomes, Health aspects, Prophylaxis -- Patient outcomes, HIV infections -- Prevention, MSM (Men who have sex with men) -- Health aspects, Emtricitabine -- Patient outcomes, Glomerular filtration rate -- Testing, Tenofovir -- Patient outcomes, HIV infection -- Prevention
Abstract

Introduction Pre?exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) ? emtricitabine (FTC) raises a lot of expectations to hamper HIV epidemic due to its high effectiveness to prevent HIV acquisition [...], : Introduction: Daily pre?exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is associated with a small but statistically significant decrease in estimated glomerular filtration rate (eGFR). We assessed the renal safety of on?demand PrEP with TDF/FTC in HIV?1 uninfected men. Methods: We used data from the randomized double?blind placebo?controlled ANRS?IPERGAY trial and its open?label extension conducted between February 2012 and June 2016 among HIV?uninfected MSM starting on?demand PrEP. Using linear mixed model, we evaluated the mean eGFR decline from baseline over time and determined risks factors associated with eGFR decline during the study. Results: During the blind phase, with a median follow?up of 9.4 months, the mean decline slope of eGFR from baseline was ?0.88 and ?1.53 mL/min/1.73 m[sup.2] per year in the placebo (n = 201) and the TDF/FTC group (n = 198) respectively, with a slope difference of 0.65 mL/min/1.73 m[sup.2] per year (p = 0.27). Including both phases, 389 participants started on?demand TDF/FTC with a median follow?up of 19.2 months and a mean decline of eGFR from baseline of ?1.14 mL/min/1.73 m[sup.2] per year (p < 0.001). The slope of eGFR reduction was not significantly different in participants with baseline eGFR ? 90 mL/min/1.73 m[sup.2] (p = 0.44), age >40 years (p = 0.24) or hypertension (p = 0.21). There was a dose?response relationship between recent tenofovir exposure and lower eGFR when considering the number of pills taken in the two months prior the visit (eGFR difference of ?0.88 mL/min/1.73 m[sup.2] between >15 pills/month vs. ?15 pills/month, p < 0.01) or plasma tenofovir concentrations at the visit (eGFR difference compared to ?2 ng/mL: >2 to ?10ng/mL: ?0.98 mL/min/1.73 m[sup.2] , >10 to ?40ng/mL: ?1.28 mL/min/1.73 m[sup.2] , >40 ng/mL: ?1.82 mL/min/1.73 m[sup.2] , p < 0.001). Three participants discontinued TDF/FTC for eGFR < 60 mL/min/1.73 m[sup.2] during the OLE phase. No case of Fanconi syndrome was reported. Conclusions: The renal safety of on?demand PrEP with TDF/FTC was good. The overall reduction and intermittent exposure to TDF/FTC may explain this good renal safety.

Published
2020
Full Text
View/download PDF

16. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

Author

Tron, L, Lert, F, Spire, B, DraySpira, R, Allègre, T, Mours, P., Riou, J.M., Sordage, M., Chennebault, J. M., Fialaire, P., Rabier, V., Froidure, M., Huguet, D., Leduc, D., Pichancourt, G., Wajsbrot, A., Bourdeaux, C., Foltzer, A., Hoen, B., HustacheMathieu, L., Abgrall, S., Barruet, R., Bouchaud, O., Chabrol, A., Mattioni, S, Mechai, F., Jeantils, V., Bernard, N., Bonnet, F., Hessamfar, M., Lacoste, D., Malvy, D., Mercié, P., Morlat, P., Paccalin, F., Pertusa, M. C., Pistone, T., Receveur, M. C., Vandenhende, M. A., Dupont, C., Freire Maresca, A., Leporrier, J., Rouveix, E., Dargere, S., de la Blanchardière, ., Martin, A., Noyon, V., Verdon, R., Rogeaux, O., Beytout, J., Gourdon, F., Laurichesse, H., Meier, F., Mortier, E., Simonpoli, A. M., Cordier, F., Delacroix, I., Garrait, V., Elharrar, B., Dominguez, S., Lascaux, A. S., Lelièvre, J. D., Levy, Y., Melica, G., Buisson, M., Piroth, L., Waldner, A., Gruat, N., Leprêtre, A., de Truchis, P., Le Du, D, Melchior, J. Cl., Sehouane, R., Troisvallets, D., Blanc, M., BocconGibod, I., Bosseray, A., Brion, J. P., Durand, F., Leclercq, P., Marion, F., Pavese, P., BrottierMancini, E., Faba, L., RoncatoSaberan, M., BollengierStragier, O., Esnault, J. L., LeautezNainville, S., Perré, P., Froguel, E., Nguessan, M., Simon, P., Colardelle, P., Doll, J., GodinCollet, C., RoussinBretagne, S., Delfraissy, J. F., Duracinsky, M., Goujard, C., Peretti, D., Quertainmont, Y., Marionneau, J., Aissi, E., Van Grunderbeeck, N, Denes, E., DucroixRoubertou, S., Genet, C., Weinbreck, P., AugustinNormand, C., Boibieux, A., Cotte, L., Ferry, T., Koffi, J., Miailhes, P., Perpoint, T., Peyramond, D., Schlienger, I., Brunel, J. M., Carbonnel, E., Chiarello, P., Livrozet, J. M., Makhloufi, D., Dhiver, C., Husson, H., Madrid, A., Ravaux, I., de Severac, M.L., Thierry Mieg, M., Tomei, C., Hakoun, S., Moreau, J., Mokhtari, S., Soavi, M. J., Faucher, O., Ménard, A., Orticoni, M., PoizotMartin, I., Soavi, M. J., Atoui, N., Baillat, V., Faucherre, V., Favier, C., Jacquet, J. M., Le Moing, V, Makinson, A., Mansouri, R., Merle, C., Elforzli, N., Allavena, C., Aubry, O., Besnier, M., Billaud, E., Bonnet, B., Bouchez, S., Boutoille, D., Brunet, C., Feuillebois, N., Lefebvre, M., MorineauLe Houssine, P, Mounoury, O., Point, P., Raffi, F., Reliquet, V., Talarmin, J. P., Ceppi, C., Cua, E., Dellamonica, P., De SalvadorGuillouet, Durant, J., Ferrando, S., MondainMiton, V., Perbost, I., Pillet, S., ProuvostKeller, B., Pradier, C., Pugliese, P., Roger, P. M., Rosenthal, E., Sanderson, F., Hocqueloux, L., Niang, M., Prazuck, T., Arsac, P., BarraultAnstett, M.F., Ahouanto, M., Bouvet, E., Castanedo, G., CharloisOu, C., Dia Kotuba, A., EidAntoun, Z., Jestin, C., Jidar, K., Joly, V., KhuongJosses, M. A., Landgraf, N., Landman, R., Lariven, S., Leprêtre, A., Lʼhériteau, F., Machado, M., Matheron, S., Michard, F., Morau, G., Pahlavan, G., Phung, B. C., Prévot, M. H., Rioux, C., Yéni, P., BaniSadr, F., Calboreanu, A., Chakvetadze, E., Salmon, D., Silbermann, B., Batisse, D., Beumont, M., Buisson, M., Castiel, P., Derouineau, J., Eliaszewicz, M., Gonzalez, G., Jayle, D., Karmochkine, M., Kousignian, P., Pavie, J., Pierre, I., Weiss, L., Badsi, E., Bendenoun, M., Cervoni, J., Diemer, M., Durel, A., Rami, A., Sellier, P., AitMohand, H., Amirat, N., Bonmarchand, M., Bourdillon, F., Breton, G., Caby, F., Grivois, J. P., Katlama, C., Kirstetter, M., Paris, L., Pichon, F., Roudière, L., Schneider, L., Samba, M. C., Seang, S., Simon, A., Stitou, H., Tubiana, R., Valantin, M. A., Bollens, D., Bottero, J., Bui, E., Campa, P., Fonquernie, L., Fournier, S., Girard, P. M., Goetschel, A., Guyon, H. F., Lacombe, K., Lallemand, F., Lefebvre, B., Maynard, J. L., Meyohas, M. C., Ouazene, Z., Pacanowski, J., Picard, O., Raguin, G., Roussard, P., Tourneur, M., Tredup, J., Valin, N., Balkan, S., Clavel, F., Colin de Verdière, N, De Castro, N., de Lastours, V., Ferret, S., Gallien, S., Garrait, V., Gérard, L., Goguel, J., Lafaurie, M., LascouxCombe, C., Molina, J. M., Oksenhendler, E., Pavie, J., Pintado, C., Ponscarme, D., Rozenbaum, W., Scemla, A., Bonnard, P., Lassel, L., Lebrette, M. G., Lyavanc, T., Mariot, P., Missonnier, R., Ohayon, M., Pialoux, G., Treilhou, M. P., Vincensini, J. P., Gilquin, J., Hadacek, B., NaitIghil, L., Nguyen, T. H., Pintado, C., Sobel, A., Viard, J. P., Zak Dit Zbar, O., Aumaître, H., Eden, A., Ferreyra, M., Lopez, F., Medus, M., Neuville, S., Saada, M., Blum, L., Perfezou, P., Arvieux, C., Chapplain, J. M., Revest, M., Souala, F., Tattevin, P., Bord, S., BorsaLebas, F., Caron, F., Chapuzet, C., Debab, Y., Gueit, I., Etienne, M., Fartoukh, C., Feltgen, K., Joly, C., RobadayVoisin, S., Suel, P., Khuong, M. A., Krausse, J., Poupard, M., Tran Van, G., Cazorla, C., Daoud, F., Fascia, P., Frésard, A., Guglielminotti, C., Lucht, F., BernardHenry, C., Cheneau, C., Lang, J. M., de Mautort, E., Partisani, M., Priester, M., Rey, D., Majerholc, C., Zucman, D., Assi, A., Lafeuillade, A., de Jaureguiberry, J. P., Gisserot, O., Aquilina, C., Prevoteau du Clary, F., Alvarez, M., Chauveau, M., Cuzin, L., Delobel, P., Garipuy, D., Labau, E., Marchou, B., Massip, P., Mularczyk, M., Obadia, M., Ajana, F., Allienne, C., Baclet, V., de la Tribonnière, X, Huleux, T., Melliez, H., Meybeck, A., Riff, B., Valette, M., Viget, N., Bastides, F., Bernard, L., Gras, G., Guadagnin, P., May, T., Rabaud, C., Dos Santos, A, P oinsignon, Y., Derradji, O., Escaut, L., Teicher, E., Vittecoq, D., Bantsima, J., CarauxPaz, P., and Patey, O.

Published
2017
Full Text
View/download PDF

17. Perception of PrEP‐related stigma in PrEP users: Results from the ANRS‐PREVENIR cohort.

Author

Protiere, C., Sagaon‐Teyssier, L., Donadille, C., Sow, A., Gaubert, G., Girard, G., Mora, M., Assoumou, L., Beniguel, L., Michels, D., Ghosn, J., Costagliola, D., Rojas Castro, D., Molina, J.‐M., and Spire, B.

Subjects
HIV prevention, HIV infections, CONFIDENCE intervals, HUMAN sexuality, MULTIVARIATE analysis, MULTIPLE regression analysis, SOCIAL stigma, SENSORY perception, PRE-exposure prophylaxis, HOMOSEXUALITY, SEX customs, SEXUAL minorities, RESEARCH funding, ODDS ratio, LONGITUDINAL method
Abstract

Introduction: Since the advent of HIV pre‐exposure prophylaxis (PrEP), stigma has been shown to be a major barrier to its uptake and adherence. It is therefore essential to define the proportion of users who consider that PrEP can negatively impact their image and the factors associated with this perception. Method: We performed a multivariable logistic regression on data from the 2567 participants in the ANRS‐PREVENIR study who answered the outcome question. Results: Almost one‐third of the sample (comprising mostly cisgender men who have sex with men [94.3%]) considered that taking PrEP could give others a negative image of them. Younger participants (adjusted odds ratio [aOR] 0.98; 95% confidence interval [CI] 0.97–0.99) and more psychologically vulnerable participants (i.e., lower self‐esteem score [aOR 0.98; 95% CI 0.96–0.99] and higher depression score [aOR 1.02; 95% CI 1.00–1.03]) were also more likely to have this perception. In contrast, participants encouraged to take PrEP by their main partner (aOR 0.67; 95% CI 0.51–0.88) and friends (aOR 0.79; 95% CI 0.66–0.95), and those who protected themselves more because they had knowledge of their most recent sexual partner's HIV status (aOR 0.83; 95% CI 0.69–0.99) and systematic use of PrEP and/or condoms during intercourse in the previous 3 months (aOR 0.80; 95% CI 0.67–0.96) were less likely to have this perception. Discussion: Given the strong interrelation between stigmatization (real or perceived), risky behaviours and adherence, our results emphasize the need for HIV prevention campaigns to promote a positive image of PrEP users. They also show that stigmatization and its effects need to be fully considered to improve HIV prevention offers to current and potential PrEP users who are most likely to be psychologically vulnerable. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Benefits and challenges of a community-based programme for women living with HIV in Mali.

Author

Perray, M., Traore, D., Riegel, L., Rojas Castro, D., Spire, B., Mora, M., Yattassaye, A., and Préau, M.

Subjects
HIV-positive persons, SOCIAL support, RESEARCH methodology, SOCIAL networks, SELF-management (Psychology), INTERVIEWING, SELF-disclosure, SELF-efficacy, RANDOMIZED controlled trials, COMMUNITY-based social services, RESEARCH funding, THEMATIC analysis, ENDOWMENTS, STATISTICAL sampling, WOMEN'S health, DISEASE management
Abstract

Gundo-So is a community-based programme developed by and for women living with HIV (WLHIV) in Mali through the ARCAD-Santé-PLUS association. It provides support, co-constructed with WLHIV, to develop strategies on whether or not to disclose their status. The aim of the ANRS-12373 research is to evaluate the impact of this programme in the short and medium term. As part of this research, semi-structured interviews were conducted with participants (14). These interviews were analysed thematically. Three themes are presented here: positive feedback from the programme, which enabled them to be listened to and supported them both psychologically and financially. The impact of the programme on the participants' social network is also described, in terms of the links made with peers met during the programme. Finally, a new perspective on issues such as disease management, which improved through the contribution of knowledge, and also through the development of psychosocial resources. The programme enabled participants to acquire psychosocial skills, the ability to effectively self-manage their condition, and strategies on whether or not to disclose their HIV status. Participants' empowerment and social support in relation to the disease were developed through the programme, particularly through the links created with other women living with HIV. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, Di Beo, Vincent, Esterle, Laure, Abgrall, Sophie, Pialoux, Gilles, Barré, Tangui, Wittkop, Linda, Salmon‐ceron, Dominique, Sogni, Philippe, Carrieri, Patrizia, Roustant, F, Platterier, P, Kmiec, I, Traore, L, Lepuil, S, Parlier, S, Sicart‐payssan, V, Bedel, E, Anriamiandrisoa, S, Pomes, C, Mole, M, Bolliot, C, Catalan, P, Mebarki, M, Adda‐lievin, A, Thilbaut, P, Ousidhoum, Y, Makhoukhi, F.Z, Braik, O, Bayoud, R, Gatey, C, Pietri, M.P, Le Baut, V, Ben Rayana, R, Bornarel, D, Chesnel, C, Beniken, D, Pauchard, M, Akel, S, Lions, C, Ivanova, A, Ritleg, A‐s, Debreux, C, Chalal, L, Zelie, J, Hue, H, Soria, A, Cavellec, M, Breau, S, Joulie, A, Fisher, P, Gohier, S, Croisier‐bertin, D, Ogoudjobi, S, Brochier, C, Thoirain‐galvan, V, Le Cam, M, Chalouni, M, Conte, V, Dequae‐merchadou, L, Desvallees, M, Gilbert, C, Gillet, S, Knight, R, Lemboub, T, Michel, L, Mora, M, Protopopescu, C, Roux, P, Tezkratt, S, Ramier, C, Sow, A, Bureau, M, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Spire, B, Valantin, V., Chas, J, Zaegel‐faucher, O, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐see, A, Bouchaud, O, Gervais, A, Lascoux‐combe, C, Goujard, C, Lacombe, K, Duvivier, C, Neau, D, Morlat, P, Bani‐sadr, F, Meyer, L, Boufassa, F, Autran, B, Roque, A.M, Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Rey, D, Peytavin, G, Petrov‐sanchez, V, Levier, A, Usubillaga, R., Terris, B, Tremeaux, P, Katlama, C, Stitou, H, Cacoub, P, Nafissa, S, Benhamou, Y, Charlotte, F, Fourati, S, Poizot‐martin, I, Zaegel, O, Laroche, H, Tamalet, C, Callard, P, Bendjaballah, F, Amiel, C, Le Pendeven, C, Marchou, B, Alric, L, Metivier, S, Selves, J, Larroquette, F, Rio, V, Haudebourg, J, Saint‐paul, M.C, de Monte, A, Giordanengo, V, Partouche, C, Martin, A, Ziol, M, Baazia, Y, Iwaka‐bande, V, Gerber, A, Uzan, M, Garipuy, D, Ferro‐collados, M.J, Nicot, F, Yazdanpanah, Y, Adle‐biassette, H, Alexandre, G, Molina, J.M, Bertheau, P, Chaix, M.L, Delaugerre, C, Maylin, S, Bottero, J, Krause, J, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Vittecocq, D, Quertainmont, Y, Teicher, E, Pallier, C, Lortholary, O, Rouzaud, C, Lourenco, J, Touam, F, Louisin, C, Avettand‐fenoel, V, Gardiennet, E, Mélard, A, Ochoa, A, Blanchard, E, Castet‐lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐buzy, L, Desclaux, A, Bioulac‐sage, P, Reigadas, S, Lacoste, D, Bonnet, F, Bernard, N, Hessamfar, M, Paccalin, J.F, Martell, C, Pertusa, M.C, Vandenhende, M, Mercié, P, Pistone, T, Receveur, M.C, Méchain, M, Duffau, P, Rivoisy, C, Faure, I, Caldato, S, Bellecave, P, Tumiotto, C, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Majerholc, C, Brollo, M, Farfour, E, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Favier, M, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Raffi, F, Allavena, C, Reliquet, V, Boutoille, D, Biron, C, Lefebvre, M, Hall, N, Bouchez, S, Rodallec, A, Le Guen, L, Hemon, C, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Valour, F, Augustin‐normand, C, Scholtes, C, Le‐thi, T.T, Chavanet, P, Duong van Huyen, M, Buisson, M, Waldner‐combernoux, A, Mahy, S, Salmon Rousseau, A, Martins, C, Galim, S, Lambert, D, Nguyen, Y, Berger, J.L, Hentzien, M, Brodard, V, Partisani, M, Batard, M.L, Cheneau, C, Priester, M, Bernard‐henry, C, de Mautort, E, Fischer, P, Gantner, P, Fafi‐kremer, S, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), ANRS CO13 HEPAVIH Study Group: F Roustant, P Platterier, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, S Anriamiandrisoa, C Pomes, M Mole, C Bolliot, P Catalan, M Mebarki, A Adda-Lievin, P Thilbaut, Y Ousidhoum, F Z Makhoukhi, O Braik, R Bayoud, C Gatey, M P Pietri, V Le Baut, R Ben Rayana, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, C Lions, A Ivanova, A-S Ritleg, C Debreux, L Chalal, J Zelie, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, S Gohier, D Croisier-Bertin, S Ogoudjobi, C Brochier, V Thoirain-Galvan, M Le Cam, M Chalouni, V Conte, L Dequae-Merchadou, M Desvallees, C Gilbert, S Gillet, R Knight, T Lemboub, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, C Ramier, A Sow, M Bureau, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, Valantin, J Chas, O Zaegel-Faucher, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Levier, R Usubillaga, B Terris, P Tremeaux, C Katlama, H Stitou, P Cacoub, S Nafissa, Y Benhamou, F Charlotte, S Fourati, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, P Callard, F Bendjaballah, C Amiel, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, V Rio, J Haudebourg, M C Saint-Paul, A De Monte, V Giordanengo, C Partouche, A Martin, M Ziol, Y Baazia, V Iwaka-Bande, A Gerber, M Uzan, D Garipuy, M J Ferro-Collados, J Selves, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, D Vittecocq, Y Quertainmont, E Teicher, C Pallier, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, E Gardiennet, A Mélard, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, A Desclaux, P Bioulac-Sage, S Reigadas, D Lacoste, F Bonnet, N Bernard, M Hessamfar, J F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Mercié, D Malvy, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, P Bioulac-Sage, S Reigadas, P Bellecave, C Tumiotto, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, P Bioulac-Sage, S Reigadas, C Majerholc, M Brollo, E Farfour, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, M Favier, C Deback, Y Lévy, S Dominguez, J D Lelièvre, A S Lascaux, G Melica, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, M Lefebvre, N Hall, S Bouchez, A Rodallec, L Le Guen, C Hemon, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, F Valour, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, C Augustin-Normand, C Scholtes, T T Le-Thi, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, A Salmon Rousseau, C Martins, S Galim, D Lambert, Y Nguyen, J L Berger, M Hentzien, V Brodard, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Fischer, P Gantner, S Fafi-Kremer, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), and Malbec, Odile

Subjects
0303 health sciences, Hepatology, business.industry, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), MEDLINE, Physical activity, medicine.disease_cause, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Virology, Medicine, 030211 gastroenterology & hepatology, business, Eating behaviour, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Clinical psychology
Abstract

International audience; No abstract available

Published
2021
Full Text
View/download PDF

20. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

Author

Couffignal, Camille, Kolta, Sami, Flamant, Martin, Cazanave, Charles, Haymann, Jean-Philippe, Mentre, France, Duval, Xavier, Leport, Catherine, Raffi, Francois, Chêne, G., Salamon, R., Moatti, J., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Cuzin, L., Dupon, M., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Hardel, L., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Assuied, A., Carrieri, P., Habak, S., Couturier, F., Jadand, C., Perrier, A., Préau, M., Protopopescu, C., Schmit, J.L., Chennebault, J.M., Faller, J.P., Magy-Bertrand, N., Chirouze, C., Humbert, P., Neau, D., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Sobel, A., Levy, Y., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Chidiac, C., Grégoire, V., Reynes, J., Fuzibet, J., Arsac, P., Bouvet, E., Bricaire, F., Monsonego, J., Girard, P.M., Guillevin, L., Herson, S., Molina, J.M., Pialoux, G., Sain, O., Sellier, P., Roblot, F., Bani-Sadr, F., Michelet, C., Lucht, F., Debord, C., Martin, T., de Jaureguiberry, J.P., Bernard, L., Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Physiologie [Bichat-Claude Bernard], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Service des Maladies Infectieuses et Tropicales A [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Hôpital Bichat, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microbiologie Fondamentale et Pathogénicité (MFP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Pharmacie de l'Hôpital Bichat, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Bell Labs (BELL), Lucent Technologies, Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Service de virologie et d'immunologie biologique, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Unité de Maladies Infectieuses et Tropicales [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service des Maladies Infectieuses et Tropicales [CHU Raymond Poincaré], Hôpital Raymond Poincaré [AP-HP], Centre Hospitalier Libourne, Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of Radiation Oncology, Université Catholique de Louvain = Catholic University of Louvain (UCL), GERES - Groupe d'Étude sur le Risque d'Exposition des Soignants aux agents infectieux - Research Group for the Prevention of Occupational Infections in Healthcare Workers [Paris, France], Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Reims (CHU Reims), University Hospital and University Jean Monnet, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Groupe d'Étude sur le Risque d'Exposition des Soignants aux agents infectieux (GERES), Cholley, Pascal, and Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière]

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, Nevirapine, nevirapine, Immunology, Cumulative Exposure, HIV Infections, 03 medical and health sciences, Absorptiometry, Photon, 0302 clinical medicine, Bone Density, Virology, Internal medicine, medicine, Humans, Prospective Studies, 030212 general & internal medicine, 030304 developmental biology, Bone mineral, 0303 health sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Incidence (epidemiology), HIV, virus diseases, Odds ratio, Middle Aged, medicine.disease, Confidence interval, 3. Good health, Cross-Sectional Studies, Infectious Diseases, Cohort, HIV-1, Coinfection, Reverse Transcriptase Inhibitors, Female, bone mineral density, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies, medicine.drug
Abstract

International audience; We assessed bone mineral density (BMD) in a cohort of human immunodeficiency virus (HIV)-positive patients after a median of 11 years of combination antiretroviral therapy (cART) and evaluated the respective role of HIV infection and antiretroviral drugs (ARVs). A cross-sectional study of 162 participants (131 male) from the ANRS-C08 cohort was performed with bone dual-energy X-ray absorptiometry (DXA) scans and renal assessment. The window of exposure to ARVs was defined as an exposure of more than six cumulative months during the last 3 years before the DXA evaluation to account for a cumulative exposure that could affect bone remodeling. The association with low BMD (Z-score < -2) was assessed by a multiple logistic regression model. The study population was 50 years (median), hepatitis C virus (HCV) (18%), and hepatitis B virus (HBV) (8%) coinfection with HIV-RNA

Published
2020
Full Text
View/download PDF

22. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

Author

Raffi, François, Le Moing, Vincent, Assuied, Alex, Habak, Sofiane, Spire, Bruno, Cazanave, Charles, Billaud, Eric, Dellamonica, Pierre, Ferry, Tristan, Fagard, Catherine, Leport, Catherine, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J. P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Hardel, L., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Assuied, A., Carrieri, P., Habak, S., Couturier, F., Jadand, C., Perrier, A., Préau, M., Protopopescu, C., Schmit, J. L., Chennebault, J. M., Faller, J. P., Chirouze, C., Magy-Bertrand, N., Humbert, P., Dupon, M., Longy-Boursier, M., Morlat, P., Neau, D., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Levy, Y., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Chidiac, C., Grégoire, V., Reynes, J., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Girard, P. M., Herson, S., Leport, C., Monsonego, J., Pialoux, G., Sain, O., Salmon, D., Sellier, P., Roblot, P., Bani-Sadr, F., Michelet, C., Lucht, F., Debord, T., Martin, T., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.

Published
2017
Full Text
View/download PDF

24. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Author

Liégeois, Florian, Boyer, S., Eymard-Duvernay, Sabrina, Carrieri, P., Kouanfack, C., Domyeum, J., Maradan, G., Ducos, J., Mpoudi-Ngole, E., Spire, B., Delaporte, E., Kuaban, C., Vidal, Laurent, Laurent, Christian, and EVOLCAM Study Group

Subjects
Treatment, Africa, Testing, HBV, virus diseases, HIV, lcsh:RC109-216, lcsh:Infectious and parasitic diseases
Abstract

Background Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon’s national antiretroviral programme. Methods A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models. Results Of 1706 patients (women 74%, median age 42 years, median time on ART 3.9 years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p

Published
2020

25. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

Author

Bastard, Jean-Philippe, Fellahi, Soraya, Couffignal, Camille, Raffi, François, Gras, Guillaume, Hardel, Lucile, Sobel, Alain, Leport, Catherine, Fardet, Laurence, Capeau, Jacqueline, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J. P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Bouteloup, V., Bouhnik, A. D., Brunet-François, C., Caron, V., Carrieri, M. P., Courcoul, M., Couturier, F., Hardel, L., Iordache, L., Kurkdji, P., Martiren, S., Préau, M., Protopopescu, C., Surzyn, J., Taieb, A., Villes, V., Schmit, J. L., Chennebault, J. M., Faller, J. P., Magy-Bertrand, N., Chirouze, C., Humbert, P., Bouchaud, O., Dupon, M., Morlat, P., Ragnaud, J. M., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Peyramond, D., Allard, C., Le Moing, V., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Monsonego, J., Girard, P. M., Guillevin, L., Herson, S., Leport, C., Meyohas, M. C., Molina, J. M., Pialoux, G., Sain, O., Salmon, D., Sellier, P., Roblot, F., Jaussaud, R., Michelet, C., Lucht, F., Rapp, C., Chesneau, C., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.

Published
2015
Full Text
View/download PDF

26. Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy]

Author

Suzan-Monti, M, Blanche, J, Boyer, S, Kouanfack, C, Delaporte, E, Bonono, R-C, Carrieri, PM, Protopopescu, C, Laurent, C, and Spire, B

Published
2015
Full Text
View/download PDF

28. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response:a sub-study of the NEAT001/ANRS143 randomized trial

Author

Dickinson L., Gurjar R., Stohr W., Bonora S., Owen A., D'Avolio A., Cursley A., Molina J. -M., Faetkenheuer G., Vandekerckhove L., Di Perri G., Pozniak A., Richert L., Raffi F., Boffito M., Dedes N., Chene G., Allavena C., Autran B., Antinori A., Bucciardini R., Vella S., Horban A., Arribas J., Babiker A. G., Pillay D., Franquet X., Schwarze S., Grarup J., Fischer A., Wallet C., Diallo A., Saillard J., Moecklinghoff C., Stellbrink H. -J., Vanleeuwen R., Gatell J., Sandstrom E., Flepp M., Ewings F., George E. C., Hudson F., Pearce G., Quercia R., Rogatto F., Leavitt R., Nguyen B. -Y., Peto T., Goebel F., Marcotullio S., Miller V., Sasieni P., Arnault F., Boucherie C., Jean D., Paniego V., Paraina F., Rouch E., Schwimmer C., Soussi M., Taieb A., Termote M., Touzeau G., Babiker A., Dodds W., Hoppe A., Kummeling I., Pacciarini F., Paton N., Russell C., Taylor K., Ward D., Aagaard B., Eid M., Gey D., Gramjensen B., Jakobsen M. -L., Jansson P. O., Jensen K., Mariajoensen Z., Moseholmlarsen E., Pahl C., Pearson M., Nielsen B. R., Reilev So. S., Christ I., Lathouwers D., Manting C., Van Leeuwen R., Mendy B., Metro A., Couffin-Cadiergues S., Knellwolf A. -L., Palmisiano L., Aznar E., Barea C., Cotarelo M., Esteban H., Girbau I., Moyano B., Ramirez M., Saiz C., Sanchez I., Yllescas M., Binelli A., Colasanti V., Massella M., Anagnostou O., Gioukari V., Touloumi G., Schmied B., Rieger A., Vetter N., Dewit S., Florence E., Gerstoft J., Mathiesen L., Katlama C., Cabie A., Cheret A., Dupon M., Ghosn J., Girard P. -M., Goujard C., Levy Y., Morlat P., Neau D., Obadia M., Perre P., Piroth L., Reynes J., Tattevin P., Ragnaud J. M., Weiss L., Yazdan Y., Yeni P., Zucman D., Esser S., Fatkenheuer G., Hoffmann C., Jessen H., Rockstroh J., Schmidt R., Stephan C., Unger S., Hatzakis A., Daikos G. L., Papadopoulos A., Skoutelis A., Banhegyi D., Mallon P., Mulcahy F., Andreoni M., Castelli F., D'Arminiomonforte A., Diperri G., Galli M., Lazzarin A., Mazzotta F., Torti C., Vullo V., Prins J., Richter C., Verhagen D., Vaneeden A., Doroana M., Antunes F., Maltez F., Sarmento-Castro R., Gonzalez Garcia J., Aldeguer J. L., Clotet B., Domingo P., Gatell J. M., Knobel H., Marquez M., Pilarmiralles M., Portilla J., Soriano V., Tellez M., Thalme A., Blaxhult A., Gisslen M., Winston A., Fox J., Gompels M., Herieka E., Johnson M., Leen C., Teague A., Williams I., Boyd M., Moller N. F., Moseholmlarsen E. F., Lemoing V., Wit F. W. N. M., Kowalska J., Berenguer J., Moreno S., Muller N. J., Torok E., Post F., Angus B., Calvez V., Boucher C., Collins S., Dunn D., Lambert S., Marcelin A. -G., Perno C. F., White E., Ammassari A., Schmidt R. E., Odermarsky M., Smith C., Thiebaut R., Delaserna J. I. B., Castagna A., De Wit S., Furrer H. -J., Mocroft A., Reiss P., Fragola V., Lauriola M., Murri R., Nieuwkerk P., Spire B., Volny-Anne A., West B., Amieva H., Llibre Codina J., Braggion M., Foca E., Dickinson, L., Gurjar, R., Stohr, W., Bonora, S., Owen, A., D'Avolio, A., Cursley, A., Molina, J. -M., Faetkenheuer, G., Vandekerckhove, L., Di Perri, G., Pozniak, A., Richert, L., Raffi, F., Boffito, M., Dedes, N., Chene, G., Allavena, C., Autran, B., Antinori, A., Bucciardini, R., Vella, S., Horban, A., Arribas, J., Babiker, A. G., Pillay, D., Franquet, X., Schwarze, S., Grarup, J., Fischer, A., Wallet, C., Diallo, A., Saillard, J., Moecklinghoff, C., Stellbrink, H. -J., Vanleeuwen, R., Gatell, J., Sandstrom, E., Flepp, M., Ewings, F., George, E. C., Hudson, F., Pearce, G., Quercia, R., Rogatto, F., Leavitt, R., Nguyen, B. -Y., Peto, T., Goebel, F., Marcotullio, S., Miller, V., Sasieni, P., Arnault, F., Boucherie, C., Jean, D., Paniego, V., Paraina, F., Rouch, E., Schwimmer, C., Soussi, M., Taieb, A., Termote, M., Touzeau, G., Babiker, A., Dodds, W., Hoppe, A., Kummeling, I., Pacciarini, F., Paton, N., Russell, C., Taylor, K., Ward, D., Aagaard, B., Eid, M., Gey, D., Gramjensen, B., Jakobsen, M. -L., Jansson, P. O., Jensen, K., Mariajoensen, Z., Moseholmlarsen, E., Pahl, C., Pearson, M., Nielsen, B. R., Reilev, So. S., Christ, I., Lathouwers, D., Manting, C., Van Leeuwen, R., Mendy, B., Metro, A., Couffin-Cadiergues, S., Knellwolf, A. -L., Palmisiano, L., Aznar, E., Barea, C., Cotarelo, M., Esteban, H., Girbau, I., Moyano, B., Ramirez, M., Saiz, C., Sanchez, I., Yllescas, M., Binelli, A., Colasanti, V., Massella, M., Anagnostou, O., Gioukari, V., Touloumi, G., Schmied, B., Rieger, A., Vetter, N., Dewit, S., Florence, E., Gerstoft, J., Mathiesen, L., Katlama, C., Cabie, A., Cheret, A., Dupon, M., Ghosn, J., Girard, P. -M., Goujard, C., Levy, Y., Morlat, P., Neau, D., Obadia, M., Perre, P., Piroth, L., Reynes, J., Tattevin, P., Ragnaud, J. M., Weiss, L., Yazdan, Y., Yeni, P., Zucman, D., Esser, S., Fatkenheuer, G., Hoffmann, C., Jessen, H., Rockstroh, J., Schmidt, R., Stephan, C., Unger, S., Hatzakis, A., Daikos, G. L., Papadopoulos, A., Skoutelis, A., Banhegyi, D., Mallon, P., Mulcahy, F., Andreoni, M., Castelli, F., D'Arminiomonforte, A., Diperri, G., Galli, M., Lazzarin, A., Mazzotta, F., Torti, C., Vullo, V., Prins, J., Richter, C., Verhagen, D., Vaneeden, A., Doroana, M., Antunes, F., Maltez, F., Sarmento-Castro, R., Gonzalez Garcia, J., Aldeguer, J. L., Clotet, B., Domingo, P., Gatell, J. M., Knobel, H., Marquez, M., Pilarmiralles, M., Portilla, J., Soriano, V., Tellez, M., Thalme, A., Blaxhult, A., Gisslen, M., Winston, A., Fox, J., Gompels, M., Herieka, E., Johnson, M., Leen, C., Teague, A., Williams, I., Boyd, M., Moller, N. F., Moseholmlarsen, E. F., Lemoing, V., Wit, F. W. N. M., Kowalska, J., Berenguer, J., Moreno, S., Muller, N. J., Torok, E., Post, F., Angus, B., Calvez, V., Boucher, C., Collins, S., Dunn, D., Lambert, S., Marcelin, A. -G., Perno, C. F., White, E., Ammassari, A., Schmidt, R. E., Odermarsky, M., Smith, C., Thiebaut, R., Delaserna, J. I. B., Castagna, A., De Wit, S., Furrer, H. -J., Mocroft, A., Reiss, P., Fragola, V., Lauriola, M., Murri, R., Nieuwkerk, P., Spire, B., Volny-Anne, A., West, B., Amieva, H., Llibre Codina, J., Braggion, M., Foca, E., Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, Global Health, APH - Personalized Medicine, APH - Mental Health, and Medical Psychology

Subjects
0301 basic medicine, Microbiology (medical), Adult, Male, medicine.medical_specialty, Anti-HIV Agents, 030106 microbiology, HIV Infections, Emtricitabine, 030226 pharmacology & pharmacy, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, immune system diseases, Internal medicine, Raltegravir Potassium, medicine, Humans, Pharmacology (medical), Tenofovir, Darunavir, Constitutive Androstane Receptor, Pharmacology, Ritonavir, biology, business.industry, Liver-Specific Organic Anion Transporter 1, virus diseases, Lopinavir, Viral Load, Raltegravir, Multidrug Resistance-Associated Protein 2, 3. Good health, NONMEM, SISTM, Infectious Diseases, Pharmacogenetics, biology.protein, Female, SLCO1B1, business, medicine.drug
Abstract

Objectives NEAT001/ANRS143 demonstrated non-inferiority of once-daily darunavir/ritonavir (800/100 mg) + twice-daily raltegravir (400 mg) versus darunavir/ritonavir + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily) in treatment-naive patients. We investigated the population pharmacokinetics of darunavir, ritonavir, tenofovir and emtricitabine and relationships with demographics, genetic polymorphisms and virological failure. Methods Non-linear mixed-effects models (NONMEM v. 7.3) were applied to determine pharmacokinetic parameters and assess demographic covariates and relationships with SNPs (SLCO3A1, SLCO1B1, NR1I2, NR1I3, CYP3A5*3, CYP3A4*22, ABCC2, ABCC10, ABCG2 and SCL47A1). The relationship between model-predicted darunavir AUC0–24 and C24 with time to virological failure was evaluated by Cox regression. Results Of 805 enrolled, 716, 720, 347 and 361 were included in the darunavir, ritonavir, tenofovir and emtricitabine models, respectively (11% female, 83% Caucasian). No significant effect of patient demographics or SNPs was observed for darunavir or tenofovir apparent oral clearance (CL/F); coadministration of raltegravir did not influence darunavir or ritonavir CL/F. Ritonavir CL/F decreased by 23% in NR1I2 63396C>T carriers and emtricitabine CL/F was linearly associated with creatinine clearance (P Conclusions Darunavir concentrations were unaltered in the presence of raltegravir and not associated with virological failure. Polymorphisms investigated had little impact on study-drug pharmacokinetics. Darunavir/ritonavir + raltegravir may be an appropriate option for patients experiencing NRTI-associated toxicity.

Published
2020
Full Text
View/download PDF

30. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author

Salmon, D., Wittkop, L., Sogni, P., Esterle, L., Trimoulet, P., Izopet, J., Serfaty, L., Paradis, V., Spire, B., Carrieri, P., Valantin, M.A., Pialoux, G., Chas, J., Poizot-Martin, I., Barange, K., Naqvi, A., Rosenthal, E., Bicart-See, A., Bouchaud, O., Gervais, A., Lascoux-Combe, C., Goujard, C., Lacombe, K., Duvivier, C., Neau, D., Morlat, P., Bani-Sadr, F., Meyer, L., Boufassa, F., Autran, B., Roque, A.M., Solas, C., Fontaine, H., Costagliola, D., Piroth, L., Simon, A., Zucman, D., Boué, F., Miailhes, P., Billaud, E., Aumaître, H., Rey, D., Peytavin, G., Petrov-Sanchez, V., Lebrasseur-Longuet, D., Usubillaga, R., Terris, B., Tremeaux, P., Katlama, C., Stitou, H., Cacoub, P., Nafissa, S., Benhamou, Y., Charlotte, F., Fourati, S., Zaegel, O., Laroche, H., Tamalet, C., Callard, P., Bendjaballah, F., Amiel, C., Le Pendeven, C., Marchou, B., Alric, L., Metivier, S., Selves, J., Larroquette, F., Rio, V., Haudebourg, J., Saint-Paul, M.C., De Monte, A., Giordanengo, V., Partouche, C., Martin, A., Ziol, M., Baazia, Y., Iwaka-Bande, V., Gerber, A., Uzan, M., Garipuy, D., Ferro-Collados, M.J., Nicot, F., Yazdanpanah, Y., Adle-Biassette, H., Alexandre, G., Molina, J.M., Bertheau, P., Chaix, M.L., Delaugerre, C., Maylin, S., Bottero, J., Krause, J., Girard, P.M., Wendum, D., Cervera, P., Adam, J., Viala, C., Vittecocq, D., Quertainmont, Y., Teicher, E., Pallier, C., Lortholary, O., Rouzaud, C., Lourenco, J., Touam, F., Louisin, C., Avettand-Fenoel, V., Gardiennet, E., Mélard, A., Ochoa, A., Blanchard, E., Castet-Lafarie, S., Cazanave, C., Malvy, D., Dupon, M., Dutronc, H., Dauchy, F., Lacaze-Buzy, L., Desclaux, A., Bioulac-Sage, P., Reigadas, S., Lacoste, D., Bonnet, F., Bernard, N., Hessamfar, J, M., Paccalin, F., Martell, C., Pertusa, M.C., Vandenhende, M., Mercié, P., Pistone, T., Receveur, M.C., Méchain, M., Duau, P., Rivoisy, C., Faure, I., Caldato, S., Bellecave, P., Tumiotto, C., Pellegrin, J.L., Viallard, J.F., Lazzaro, E., Greib, C., Majerholc, C., Brollo, M., Farfour, E., Polo Devoto, J., Kansau, I., Chambrin, V., Pignon, C., Berroukeche, L., Fior, R., Martinez, V., Abgrall, S., Favier, M., Deback, C., Lévy, Y., Dominguez, S., Lelièvre, J.D., Lascaux, A.S., Melica, G., Raffi, F., Allavena, C., Reliquet, V., Boutoille, D., Biron, C., Lefebvre, M., Hall, N., Bouchez, S., Rodallec, A., Le Guen, L., Hemon, C., Peyramond, D., Chidiac, C., Ader, F., Biron, F., Boibieux, A., Cotte, L., Ferry, T., Perpoint, T., Koffi, J., Zoulim, F., Bailly, F., Lack, P., Maynard, M., Radenne, S., Amiri, M., Valour, F., Augustin-Normand, C., Scholtes, C., Le-Thi, T.T., Chavanet, P., Duong Van Huyen, M., Buisson, M., Waldner-Combernoux, A., Mahy, S., Binois, R., Simonet-Lann, A.L., Croisier-Bertin, D., Salmon Rousseau, A., Martins, C., Galim, S., Lambert, D., Nguyen, Y., Berger, J.L., Hentzien, M., Brodard, V., Partisani, M., Batard, M.L., Cheneau, C., Priester, M., Bernard-Henry, C., de Mautort, E., Gantner et S Fafi-Kremer, P., Roustant, F., Platterier, P., Kmiec, I., Traore, L., Lepuil, S., Parlier, S., Sicart-Payssan, V., Bedel, E., Anriamiandrisoa, S., Pomes, C., Mole, M., Bolliot, C., Catalan, P., Mebarki, M., Adda-Lievin, A., Thilbaut, P., Ousidhoum, Y., Makhoukhi, F.Z., Braik, O., Bayoud, R., Gatey, C., Pietri, M.P., Le Baut, V., Ben Rayana, R., Bornarel, D., Chesnel, C., Beniken, D., Pauchard, M., Akel, S., Lions, C., Ivanova, A., Ritleg, A.-S., Debreux, C., Chalal, L., Zelie, J., Hue, H., Soria, A., Cavellec, M., Breau, S., Joulie, A., Fisher, P., Gohier, S., Ogoudjobi, S., Brochier, C., Thoirain-Galvan, V., Le Cam, M., Chalouni, M., Conte, V., Dequae-Merchadou, L., Desvallees, M., Gilbert, C., Gillet, S., Knight, R., Lemboub, T., Marcellin, F., Michel, L., Mora, M., Protopopescu, C., Roux, P., Tezkratt, S., Barré, T., Baudoin, M., Santos, M., Di Beo, V., Nishimwe, M., Marcellin, Fabienne, Di Beo, Vincent, Aumaitre, Hugues, Mora, Marion, Wittkop, Linda, Duvivier, Claudine, Protopopescu, Camelia, Lacombe, Karine, Esterle, Laure, Berenger, Cyril, Gilbert, Camille, Bouchaud, Olivier, Poizot-Martin, Isabelle, Sogni, Philippe, Salmon-Ceron, Dominique, and Carrieri, Patrizia

Published
2020
Full Text
View/download PDF

31. Understanding how peer relationships influence peerdelivered HIV prevention interventions among Ugandan female sex workers: a case study from HIV self-testing

Author

Eubanks, A., Mimi, M., Dembélé Keita, B, Anoma, C., Dah, T.T.E., Mensah, E., Maradan, G., Bourrelly, M., Mora, M., Riegel, L., Rojas Castro, D., Yaya, I., Spire, B., Laurent, C., Sagaon-Teyssier, L., Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ARCAD-SIDA [Bamako, Mali], Espace Confiance [Abidjan, Côte d’Ivoire], Centre Muraz [Bobo-Dioulasso, Burkina Faso], Espoir Vie Togo [Lomé, Togo], Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Coalition PLUS [Pantin, France], Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), and Malbec, Odile

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience; Background: Access to PrEP for men who have sex with men (MSM) is a public health priority. PrEP rollout for MSM in West Africa is confronted by unknowns concerning the feasibility in this context, due to the highly vulnerable nature of MSM (stigma, precarity, high-risk sex). We aimed to estimate the attrition rate and identify the factors associated with loss to follow-up (LTFU) in a cohort of MSM on PrEP in West Africa.Methods: Since 2017, CohMSM-PrEP has offered a comprehensive prevention package for MSM in Mali, Cote d’Ivoire, Burkina Faso, and Togo. Quarterly follow-up includes PrEP (daily or event-driven) and socio-behavioral data collection. Participants from a previous MSM cohort and new participants were enrolled. LTFU was defined as not attending the last two scheduled follow-up visits. The Kaplan-Meier technique and log-rank test were used to estimate time to LTFU and to test for significance between groups. The Cox proportional hazards regression model was used to determine predictors of LTFU and adjusted by confounders.Results: 585 participants were recruited from November 2017-January 2020. The median follow-up time was 15.6 months. During this period, 119 participants were LTFU (20%). The median follow-up time for LTFU participants was 3 months. The attrition rate was 1.8/100 person-years. Newly enrolled participants left the cohort at a higher rate than former CohMSM participants (p-value

Published
2021
Full Text
View/download PDF

32. Intimate partner violence by men living with HIV in Cameroon: Prevalence, associated factors and implications for HIV transmission risk (ANRS-12288 EVOLCAM)

Author

Fiorentino, Marion, Sow, A., Sagaon Teyssier, Luis, Mora, M., Mengue, M. T., Vidal, Laurent, Kuaban, C., March, Laura, Laurent, Christian, Spire, B., Boyer, S., and EVOLCam Study Group

Subjects
Science, education, mental disorders, population characteristics, Medicine, social sciences, behavioral disciplines and activities
Abstract

ObjectivesIntimate partner violence (IPV) against women is frequent in Central Africa and may be a HIV infection risk factor. More data on HIV-positive men (MLHIV) committing IPV are needed to develop perpetrator-focused IPV and HIV prevention interventions. We investigated the relationship between IPV and HIV transmission risk and IPV-associated factors.MethodsWe used data from the cross-sectional survey EVOLCam which was conducted in Cameroonian outpatient HIV structures in 2014. The study population comprised MLHIV declaring at least one sexual partner in the previous year. Using principal component analysis, we built three variables measuring, respectively, self-reported MLHIV-perpetrated psychological and physical IPV (PPV), severe physical IPV (SPV), and sexual IPV (SV). Ordinal logistic regressions helped investigate: i) the relationship between HIV transmission risk (defined as unstable aviremia and inconsistent condom use) and IPV variables, ii) factors associated with each IPV variable.ResultsPPV, SPV and SV were self-reported by 28, 15 and 11% of the 406 study participants, respectively. IPV perpetrators had a significantly higher risk of transmitting HIV than non-IPV perpetrators. Factors independently associated with IPV variables were: i) socio-demographic, economic and dyadic factors, including younger age (PPV and SPV), lower income (PPV), not being the household head (SPV and SV), living with a main partner (SPV), and having a younger main partner (SPV); ii) sexual behaviors, including ≥2 partners in the previous year (PPV and SPV), lifetime sex with another man (SPV), inconsistent condom use (SV), and >20 partners during lifetime (SV); iii) HIV-related stigma (PPV and SV).ConclusionIPV perpetrators had a higher risk of transmitting HIV and having lifetime and recent risky sexual behaviors. Perpetrating IPV was more frequent in those with socioeconomic vulnerability and self-perceived HIV-related stigma. These findings highlight the need for interventions to prevent IPV by MLHIV and related HIV transmission to their(s) partner(s).

Published
2021

35. Vulnerability, unsafe sex and non-adherence to HAART: Evidence from a large sample of French HIV/AIDS outpatients

Author

Peretti-Watel, P., Spire, B., Schiltz, M.A., Bouhnik, A.D., Heard, I., Lert, F., and Obadia, Y.

Subjects
Anti-HIV agents -- Analysis, Antiviral agents -- Analysis, Highly active antiretroviral therapy -- Analysis, AIDS (Disease) -- Analysis, HIV (Viruses) -- Analysis, Health, Social sciences
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.socscimed.2005.10.020 Byline: P. Peretti-Watel (a)(b), B. Spire (a)(b), M.A. Schiltz (c), A.D. Bouhnik (a)(b), I. Heard (d), F. Lert (e), Y. Obadia (a)(b) Keywords: HIV/AIDS; HAART; Adherence; Unsafe sex; France Abstract: Current socio-behavioural research in HIV-infected people has tried to identify patients with 'high-risk' profiles, i.e. who simultaneously exhibit non-adherence to highly active anti-retroviral therapy (HAART) and unsafe sex with serodiscordant partners. We challenged this approach by investigating the correlates of both behaviours, for homosexual men, heterosexual men and heterosexual women separately, among a representative sample of 4963 HIV-infected people in France. Variables introduced in the analysis dealt with patients' background and daily life, with a focus on situations of economic, social and personal vulnerability. Overall, 2932 patients agreed to participate, and 1809 were both receiving HAART and sexually active. Among heterosexual women, non-adherence and unsafe sex appeared as joint outcomes of similar situations of vulnerability. Among heterosexual men, these behaviours were weakly correlated and shared some predictors related to situations of vulnerability. Among homosexual men, non-adherence and unsafe sex were not correlated and had distinct determinants. Situations of vulnerability, the context and the motives of unsafe sex, as well as factors associated with non-adherence and unsafe sex varied greatly with gender and sexual preference. Theoretical models used for designing behavioural interventions should take into account this diversity. Author Affiliation: (a) Regional Centre for Disease Control of South-Eastern France, Marseille, France (b) Health and Medical Research National Institute, Research Unit 379, 'Social Sciences Applied to Medical Innovation', Institut Paoli Calmettes, Marseille, France (c) National Centre of Scientific Research (CNRS-CERMES) and Health and Medical Research National Institute, Research Unit 504 (d) Health and Medical Research National Institute, Research Unit 430, European Hospital Georges Pompidou, Paris, France (e) Health and Medical Research National Institute, Research Unit 88, Paris, France

Published
2006

39. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

Author

Chalouni, Mathieu, primary, Pol, Stanislas, additional, Sogni, Philippe, additional, Fontaine, Hélène, additional, Lacombe, Karine, additional, Marc-Lacombe, Jean, additional, Esterle, Laure, additional, Dorival, Celine, additional, Bourlière, Marc, additional, Bani-Sadr, Firouzé, additional, de Ledinghen, Victor, additional, Zucman, David, additional, Larrey, Dominique, additional, Salmon, Dominique, additional, Carrat, Fabrice, additional, Wittkop, Linda, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaitre, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, and Lebrasseur-Longuet, D., additional

Published
2021
Full Text
View/download PDF

40. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy

Author

Masquelier, Bernard, Taieb, Audrey, Reigadas, Sandrine, Marchou, Bruno, Cheneau, Christine, Spire, Bruno, Charpentier, Charlotte, Leport, Catherine, Raffi, François, Chêne, Geneviève, Descamps, Diane, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J.-P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Reboud, P., Couffin-Cadiergues, Sandrine, Marchand, Lucie, Bouteloup, V., Bouhnik, A. D., Brunet-François, C., Caron, V., Carrieri, M. P., Courcoul, M., Couturier, F., Hardel, L., Iordache, L., Kurkdji, P., Martiren, S., Préau, M., Protopopescu, C., Surzyn, J., Taieb, A., Villes, V., Schmit, J. L., Chennebault, J. M., Faller, J. P., Mgy-Bertrand, N., Hoen, B., Drobachef, Bouchaud, O., Dupon, M., Longy-Boursier, Morlat, P., Ragnaud, J. M., Granier, P., Garré, M., Verdon, R., Merrien, D., Devidas, A., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Peyramond, D., Allard, C., Reynes, J., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Bergmann, P., Cabane, J., Monsonego, J., Girard, P. M., Guillevin, L., Herson, S., Leport, C., Meyohas, M. C., Molina, J. M., Pialoux, G., Salmon, D., Roblot, P., Jaussaud, R., Michelet, C., Lucht, F., Debord, T., Rey, D., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.

Published
2011
Full Text
View/download PDF

42. How PrEP users constitute a community in the MSM population through their specific experience and management of stigmatization. The example of the French ANRS-PREVENIR study

Author

Puppo, C., primary, Spire, B., additional, Morel, S., additional, Génin, M., additional, Béniguel, L., additional, Costagliola, D., additional, Ghosn, J., additional, Mabire, X., additional, Molina, J. M., additional, Rojas Castro, D., additional, and Préau, M., additional

Published
2020
Full Text
View/download PDF

43. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, primary, Di Beo, Vincent, additional, Aumaitre, Hugues, additional, Mora, Marion, additional, Wittkop, Linda, additional, Duvivier, Claudine, additional, Protopopescu, Camelia, additional, Lacombe, Karine, additional, Esterle, Laure, additional, Berenger, Cyril, additional, Gilbert, Camille, additional, Bouchaud, Olivier, additional, Poizot-Martin, Isabelle, additional, Sogni, Philippe, additional, Salmon-Ceron, Dominique, additional, Carrieri, Patrizia, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaître, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, Lebrasseur-Longuet, D., additional, Usubillaga, R., additional, Terris, B., additional, Tremeaux, P., additional, Katlama, C., additional, Stitou, H., additional, Cacoub, P., additional, Nafissa, S., additional, Benhamou, Y., additional, Charlotte, F., additional, Fourati, S., additional, Zaegel, O., additional, Laroche, H., additional, Tamalet, C., additional, Callard, P., additional, Bendjaballah, F., additional, Amiel, C., additional, Le Pendeven, C., additional, Marchou, B., additional, Alric, L., additional, Metivier, S., additional, Selves, J., additional, Larroquette, F., additional, Rio, V., additional, Haudebourg, J., additional, Saint-Paul, M.C., additional, De Monte, A., additional, Giordanengo, V., additional, Partouche, C., additional, Martin, A., additional, Ziol, M., additional, Baazia, Y., additional, Iwaka-Bande, V., additional, Gerber, A., additional, Uzan, M., additional, Garipuy, D., additional, Ferro-Collados, M.J., additional, Nicot, F., additional, Yazdanpanah, Y., additional, Adle-Biassette, H., additional, Alexandre, G., additional, Molina, J.M., additional, Bertheau, P., additional, Chaix, M.L., additional, Delaugerre, C., additional, Maylin, S., additional, Bottero, J., additional, Krause, J., additional, Girard, P.M., additional, Wendum, D., additional, Cervera, P., additional, Adam, J., additional, Viala, C., additional, Vittecocq, D., additional, Quertainmont, Y., additional, Teicher, E., additional, Pallier, C., additional, Lortholary, O., additional, Rouzaud, C., additional, Lourenco, J., additional, Touam, F., additional, Louisin, C., additional, Avettand-Fenoel, V., additional, Gardiennet, E., additional, Mélard, A., additional, Ochoa, A., additional, Blanchard, E., additional, Castet-Lafarie, S., additional, Cazanave, C., additional, Malvy, D., additional, Dupon, M., additional, Dutronc, H., additional, Dauchy, F., additional, Lacaze-Buzy, L., additional, Desclaux, A., additional, Bioulac-Sage, P., additional, Reigadas, S., additional, Lacoste, D., additional, Bonnet, F., additional, Bernard, N., additional, Hessamfar, J, M., additional, Paccalin, F., additional, Martell, C., additional, Pertusa, M.C., additional, Vandenhende, M., additional, Mercié, P., additional, Pistone, T., additional, Receveur, M.C., additional, Méchain, M., additional, Duau, P., additional, Rivoisy, C., additional, Faure, I., additional, Caldato, S., additional, Bellecave, P., additional, Tumiotto, C., additional, Pellegrin, J.L., additional, Viallard, J.F., additional, Lazzaro, E., additional, Greib, C., additional, Majerholc, C., additional, Brollo, M., additional, Farfour, E., additional, Polo Devoto, J., additional, Kansau, I., additional, Chambrin, V., additional, Pignon, C., additional, Berroukeche, L., additional, Fior, R., additional, Martinez, V., additional, Abgrall, S., additional, Favier, M., additional, Deback, C., additional, Lévy, Y., additional, Dominguez, S., additional, Lelièvre, J.D., additional, Lascaux, A.S., additional, Melica, G., additional, Raffi, F., additional, Allavena, C., additional, Reliquet, V., additional, Boutoille, D., additional, Biron, C., additional, Lefebvre, M., additional, Hall, N., additional, Bouchez, S., additional, Rodallec, A., additional, Le Guen, L., additional, Hemon, C., additional, Peyramond, D., additional, Chidiac, C., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Cotte, L., additional, Ferry, T., additional, Perpoint, T., additional, Koffi, J., additional, Zoulim, F., additional, Bailly, F., additional, Lack, P., additional, Maynard, M., additional, Radenne, S., additional, Amiri, M., additional, Valour, F., additional, Augustin-Normand, C., additional, Scholtes, C., additional, Le-Thi, T.T., additional, Chavanet, P., additional, Duong Van Huyen, M., additional, Buisson, M., additional, Waldner-Combernoux, A., additional, Mahy, S., additional, Binois, R., additional, Simonet-Lann, A.L., additional, Croisier-Bertin, D., additional, Salmon Rousseau, A., additional, Martins, C., additional, Galim, S., additional, Lambert, D., additional, Nguyen, Y., additional, Berger, J.L., additional, Hentzien, M., additional, Brodard, V., additional, Partisani, M., additional, Batard, M.L., additional, Cheneau, C., additional, Priester, M., additional, Bernard-Henry, C., additional, de Mautort, E., additional, Gantner et S Fafi-Kremer, P., additional, Roustant, F., additional, Platterier, P., additional, Kmiec, I., additional, Traore, L., additional, Lepuil, S., additional, Parlier, S., additional, Sicart-Payssan, V., additional, Bedel, E., additional, Anriamiandrisoa, S., additional, Pomes, C., additional, Mole, M., additional, Bolliot, C., additional, Catalan, P., additional, Mebarki, M., additional, Adda-Lievin, A., additional, Thilbaut, P., additional, Ousidhoum, Y., additional, Makhoukhi, F.Z., additional, Braik, O., additional, Bayoud, R., additional, Gatey, C., additional, Pietri, M.P., additional, Le Baut, V., additional, Ben Rayana, R., additional, Bornarel, D., additional, Chesnel, C., additional, Beniken, D., additional, Pauchard, M., additional, Akel, S., additional, Lions, C., additional, Ivanova, A., additional, Ritleg, A.-S., additional, Debreux, C., additional, Chalal, L., additional, Zelie, J., additional, Hue, H., additional, Soria, A., additional, Cavellec, M., additional, Breau, S., additional, Joulie, A., additional, Fisher, P., additional, Gohier, S., additional, Ogoudjobi, S., additional, Brochier, C., additional, Thoirain-Galvan, V., additional, Le Cam, M., additional, Chalouni, M., additional, Conte, V., additional, Dequae-Merchadou, L., additional, Desvallees, M., additional, Gilbert, C., additional, Gillet, S., additional, Knight, R., additional, Lemboub, T., additional, Marcellin, F., additional, Michel, L., additional, Mora, M., additional, Protopopescu, C., additional, Roux, P., additional, Tezkratt, S., additional, Barré, T., additional, Baudoin, M., additional, Santos, M., additional, Di Beo, V., additional, and Nishimwe, M., additional

Published
2020
Full Text
View/download PDF

50. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse : a post-hoc analysis of the ANRS IPERGAY trial

Author

Antoni, G., Tremblay, C., Delaugerre, C., Charreau, I., Cua, E., Castro, D. R., Raffi, F., Chas, J., Huleux, T., Spire, B., Capitant, C., Cotte, L., Meyer, L., Molina, J. M., Sagaon Teyssier, Luis (collab.), and ANRS Ipergay Study Group

Abstract

Background ANRS IPERGAY found that on-demand pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus emtricitabine was associated with an 86% relative reduction of HIV-1 incidence compared with placebo among men who have sex with men at high risk of HIV. We aimed to investigate whether on-demand PrEP was similarly effective among individuals with lower exposure to HIV risk. Methods Participants in the ANRS IPERGAY trial were randomly assigned to receive PrEP (fixed-dose combination of 300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine per pill) or placebo. The primary endpoint was the diagnosis of HIV-1 infection. Pill uptake was assessed by counting returned pills at each follow-up and by estimating tenofovir concentration from frozen plasma samples. Participants were interviewed at each visit to assess the pattern of PrEP use. All participants enrolled in the modified intention-to-treat population of the double-blind phase of the ANRS IPERGAY trial were eligible for this post-hoc analysis. We calculated the total follow-up time for periods of less frequent sexual intercourse with high PrEP adherence (15 pills or fewer per month taken systematically or often during sexual intercourse). To estimate the time of HIV acquisition, fourth-generation HIV-1/2 ELISA assays, plasma HIV-1 RNA assays, and western blot analyses were done with use of frozen samples, and the stage of HIV infection was defined according to Fiebig staging. HIV incidence was compared between the two treatment groups among individuals who had less frequent sexual intercourse with high PrEP adherence. The ANRS IPERGAY trial is registered with ClinicalTrials.gov, NCT01473472. Findings 400 participants who were randomly assigned to receive PrEP (n=199) or placebo (n=201) between Feb 22, 2012, and Oct 17, 2014, were included in this analysis. 270 participants had at least one period of less frequent sexual intercourse with high PrEP adherence during the study, representing 134 person-years of follow-up and 31% of the total study follow-up. During these periods, participants in both groups reported a median of 5.0 (IQR 2.0-10.0) episodes of sexual intercourse per month and used a median of 9.5 (6.0-13.0) pills per month. Six HIV-1 infections were diagnosed in the placebo group (HIV incidence of 9.2 per 100 person-years; 95% CI 3.4-20.1) and none were diagnosed in the tenofovir disoproxil fumarate plus emtricitabine arm (HIV incidence of 0 per 100 person-years; 0-5.4; p=0.013), with a relative reduction of HIV incidence of 100% (95% CI 39-100). Interpretation A choice between daily or on-demand PrEP regimens could be offered to men who have sex with men who have less frequent sexual intercourse.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results